Pharmaceuticals

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

bexib
By bexib 0 Min Read

In this interview, Melissa Krebs, CEO and Founder of GelSana, discusses the journey of developing a cutting-edge biomaterial that has the potential to transform the $78 billion wound care market.

You Might Also Like

The Michael J. Fox Foundation and Parkinson’s UK award $5.2 million to Mission Therapeutics to research potential treatments for Parkinson’s disease

Regenxbio CEO to step down after 15 years

Pharma Pulse 6/12/24: Challenges in oncology trials, the role of AI in patient-pharmacist interactions, and more

ChatGPT outperforms residents in assessing pediatric respiratory illness

US Pharma and Biotech Summit 2024: Artificial Intelligence and Machine Learning Through the Eyes of the FDA Part II

Share This Article
Previous Article Calculated Risk: Update: Lumber prices unchanged year-over-year
Next Article Efficient and Inefficient – Econlib
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Singapore’s GFTN partners with Odisha to establish fintech hub
Fintech
Lazada and Peak3 bring digital insurance to over 5 million people in Southeast Asia
Fintech
Mandarin Oriental’s international chef praises Williams’ global credibility
Hospitality & Tourism
BTN to fully acquire Victoria Sharia Bank by mid-2025
Fintech